These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 15187582)
21. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2. Ball SE; Ahern D; Scatina J; Kao J Br J Clin Pharmacol; 1997 Jun; 43(6):619-26. PubMed ID: 9205822 [TBL] [Abstract][Full Text] [Related]
22. Effect of paroxetine on marble-burying behavior in mice. Shinomiya K; Fujii Y; Sugimoto Y; Azuma N; Tokunaga S; Kitazumi K; Kamei C Methods Find Exp Clin Pharmacol; 2005 Dec; 27(10):685-7. PubMed ID: 16395417 [TBL] [Abstract][Full Text] [Related]
23. 'Compulsive' lever pressing in rats is enhanced following lesions to the orbital cortex, but not to the basolateral nucleus of the amygdala or to the dorsal medial prefrontal cortex. Joel D; Doljansky J; Schiller D Eur J Neurosci; 2005 Apr; 21(8):2252-62. PubMed ID: 15869522 [TBL] [Abstract][Full Text] [Related]
24. Fluvoxamine: a selective serotonin re-uptake inhibitor for the treatment of obsessive-compulsive disorder. Dell'Osso B; Allen A; Hollander E Expert Opin Pharmacother; 2005 Dec; 6(15):2727-40. PubMed ID: 16316311 [TBL] [Abstract][Full Text] [Related]
25. 5-HT1A-receptor subtype mediates the effect of fluvoxamine, a selective serotonin reuptake inhibitor, on marble-burying behavior in mice. Ichimaru Y; Egawa T; Sawa A Jpn J Pharmacol; 1995 May; 68(1):65-70. PubMed ID: 7494384 [TBL] [Abstract][Full Text] [Related]
26. The guinea pig forced swim test as a new behavioral despair model to characterize potential antidepressants. Wicke KM; Rex A; Jongen-Relo A; Groth I; Gross G Psychopharmacology (Berl); 2007 Nov; 195(1):95-102. PubMed ID: 17646967 [TBL] [Abstract][Full Text] [Related]
27. Effects of acute fluoxetine, paroxetine and desipramine on rats tested on the elevated plus-maze. Drapier D; Bentué-Ferrer D; Laviolle B; Millet B; Allain H; Bourin M; Reymann JM Behav Brain Res; 2007 Jan; 176(2):202-9. PubMed ID: 17095104 [TBL] [Abstract][Full Text] [Related]
28. Indices of extinction-induced "depression" after operant learning using a runway vs. a cued free-reward delivery schedule. Topic B; Kröger I; Vildirasova PG; Huston JP Neurobiol Learn Mem; 2012 Nov; 98(4):329-40. PubMed ID: 23044457 [TBL] [Abstract][Full Text] [Related]
29. The role of the cholinergic system in the signal attenuation rat model of obsessive-compulsive disorder. Yankelevitch-Yahav R; Joel D Psychopharmacology (Berl); 2013 Nov; 230(1):37-48. PubMed ID: 23685859 [TBL] [Abstract][Full Text] [Related]
30. Fluvoxamine in the treatment of obsessive-compulsive disorder and related conditions. Goodman WK; Ward H; Kablinger A; Murphy T J Clin Psychiatry; 1997; 58 Suppl 5():32-49. PubMed ID: 9184625 [TBL] [Abstract][Full Text] [Related]
31. Evaluation of animal models of obsessive-compulsive disorder: correlation with phasic dopamine neuron activity. Sesia T; Bizup B; Grace AA Int J Neuropsychopharmacol; 2013 Jul; 16(6):1295-307. PubMed ID: 23360787 [TBL] [Abstract][Full Text] [Related]
32. [New antidepressive agents]. LaBranche S Union Med Can; 1995 Nov; 124(3):8-13. PubMed ID: 8560639 [No Abstract] [Full Text] [Related]
33. [Effects of co-administration of an antidepressant and an anxiolytic drug in the "learned helplessness" paradigm: importance of hydroxyzine]. Martin P; Guillou N; Lacroix P; Billardon M Encephale; 1996; 22(4):270-9. PubMed ID: 9035982 [TBL] [Abstract][Full Text] [Related]
34. The selective serotonin re-uptake inhibitors fluvoxamine and paroxetine differ in sexual inhibitory effects after chronic treatment. Waldinger MD; van De Plas A; Pattij T; van Oorschot R; Coolen LM; Veening JG; Olivier B Psychopharmacology (Berl); 2002 Mar; 160(3):283-9. PubMed ID: 11889497 [TBL] [Abstract][Full Text] [Related]
35. Selective serotonin reuptake inhibitors fluvoxamine and paroxetine restore forced exercise-induced temperature dysregulation in ovariectomized mice. Ikeda M; Egawa T; Yamauchi A; Sohda Y; Koga A; Tominaga K; Shuto H; Kataoka Y Eur J Pharmacol; 2008 Jan; 579(1-3):439-44. PubMed ID: 18155696 [TBL] [Abstract][Full Text] [Related]
36. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder. Pigott TA; Seay SM J Clin Psychiatry; 1999 Feb; 60(2):101-6. PubMed ID: 10084636 [TBL] [Abstract][Full Text] [Related]
37. The signal attenuation rat model of obsessive-compulsive disorder: a review. Joel D Psychopharmacology (Berl); 2006 Jul; 186(4):487-503. PubMed ID: 16718482 [TBL] [Abstract][Full Text] [Related]
38. [Obsessive-compulsive disorders in general practice. How the obsessive-compulsive neurotic is revealed by skin and hair]. Kordon A; Broocks A; Hohagen F MMW Fortschr Med; 2003 May; 145 Suppl 2():4-7. PubMed ID: 14579475 [TBL] [Abstract][Full Text] [Related]
39. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. Skinner MH; Kuan HY; Pan A; Sathirakul K; Knadler MP; Gonzales CR; Yeo KP; Reddy S; Lim M; Ayan-Oshodi M; Wise SD Clin Pharmacol Ther; 2003 Mar; 73(3):170-7. PubMed ID: 12621382 [TBL] [Abstract][Full Text] [Related]